Swiss Life Sciences Stock News

If you are wondering whether Amrize at around CHF44.64 is priced attractively or not, the key question is how its current share price compares with its underlying business value. Recently, the stock has been relatively steady, with a 1.1% return over the last 30 days and a 3.0% decline over the last 7 days. This may reflect shifting views on its near term prospects and risk. Recent news flow on Amrize has focused more on maintaining investor visibility than on any single transformational...

When companies post strong earnings, the stock generally performs well, just like Burkhalter Holding AG's ( VTX:BRKN...

Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be...

Nestlé (SWX:NESN) is back in focus after first quarter sales exceeded expectations, supported by 3.5% organic growth across categories like coffee and snacks, while management reaffirmed its full year outlook despite currency and recall headwinds. See our latest analysis for Nestlé. The recent first quarter beat and portfolio reshaping, including the planned Blue Bottle Coffee sale and potential ice cream exit, have supported a 90 day share price return of 12.01%. This comes even as the 1...

Cosmo (SWX:COPN) is back in focus after reporting 12 month Phase III results for its Clascoterone 5% topical solution in male androgenetic alopecia, highlighting long term safety, ongoing efficacy and preparation for global regulatory filings. See our latest analysis for Cosmo. The latest clinical update comes after a mixed period in the market, with a 23.6% 1 month share price return and a 16.99% 3 month decline. Meanwhile, the 1 year total shareholder return sits at 111.93%, suggesting...

Wondering if Roche Holding at around CHF324.90 is offering fair value or if the price is running ahead of the story? This article focuses squarely on what that share price may or may not reflect. Over the past week the stock returned 3.6% and over the last month 6.2%. The 1 year return stands at 27.7%, and the year to date move is close to flat at a 0.2% decline. Recent news flow around Roche Holding has kept attention on the stock, from ongoing discussion of its position in global...

Readers hoping to buy Walliser Kantonalbank ( VTX:WKBN ) for its dividend will need to make their move shortly, as the...

ABB launched its HiPerGuard 34.5kV medium voltage UPS for AI data centers, enabling direct-to-grid power connections. The system is microgrid ready and is the first in its class to receive UL 9540 certification for safety and performance. ABB reported record order intake and cash flow alongside this product launch, highlighting strong operating momentum. ABB (SWX:ABBN) is drawing attention with this data center focused UPS launch while its shares trade around CHF78.1. The stock has...

As European markets experience a positive upswing, highlighted by gains in major indices like Germany’s DAX and France’s CAC 40, investors are closely monitoring the region's economic outlook amid geopolitical developments. In this environment, growth companies with substantial insider ownership can be particularly appealing as they often signal strong confidence from those closest to the business operations.

Temenos AG ( VTX:TEMN ) just released its quarterly report and things are looking bullish. Temenos beat earnings, with...

Schindler Holding (SWX:SCHN) has opened Q1 2026 earnings season with a clean set of headline numbers, coming off Q4 2025 revenue of CHF 2.8b and basic EPS of CHF 2.46, supported by trailing 12 month revenue of CHF 11.0b and EPS of CHF 9.48 as earnings grew 6.8% over the past year. Over recent quarters the company has seen revenue move within a CHF 2.7b to CHF 2.9b range while quarterly EPS has held between CHF 2.16 and CHF 2.46, which points to a business that is leaning on steady...

Some investors may be wondering whether Novartis at around CHF116 per share is still good value, or if most of the opportunity is already reflected in the price. The stock has had a 1% decline over the past week and past month, while posting returns of 7.2% year to date and 30.2% over the last year. This may catch the eye of investors weighing reward against risk. Recent headlines have highlighted Novartis as a large, established player in global pharmaceuticals. This keeps it on the radar...

Wondering whether UBS Group at around CHF33.54 is still good value or starting to look stretched? This overview is built to help you frame that question clearly. The stock has had mixed recent performance, with a 0.9% decline over the last 7 days, a 14.0% gain over the last 30 days, a 12.1% decline year to date, and a 42.1% return over the last year, alongside multi year returns of 102.9% over 3 years and 172.7% over 5 years. Recent coverage of UBS Group has focused on its position as a...

As European markets experience a positive upswing, with the STOXX Europe 600 Index rising by 1.91% amid easing geopolitical tensions and steady corporate earnings, investors are increasingly looking to dividend stocks as a reliable income source. In this context, selecting dividend stocks that offer stable yields can be particularly appealing for those seeking consistent returns in an environment where economic forecasts remain cautious.

Roche Holding (SWX:ROP) is back in focus after regulators accepted a key filing for Gazyva in systemic lupus erythematosus, along with new Phase III data for fenebrutinib and Enspryng in multiple sclerosis and MOGAD. See our latest analysis for Roche Holding. Despite a series of positive trial readouts and the FDA accepting the Gazyva filing, Roche Holding’s CHF313.1 share price has a 30 day share price return of 3.03%, a 90 day share price return of 10%, and a 1 year total shareholder return...

Readers hoping to buy SFS Group AG ( VTX:SFSN ) for its dividend will need to make their move shortly, as the stock is...

Q1 results and outlook shift ABB (SWX:ABBN) drew fresh investor attention after reporting first quarter results and raising its full year revenue expectations, supported by strong electrification orders tied to AI related data center demand. The company reported first quarter revenue of US$8,734 million and net income of US$1,324 million, with electrification orders up 44% and comparable orders up 24%, including very strong order growth from data center projects. See our latest analysis for...

APG|SGA SA ( VTX:APGN ) stock is about to trade ex-dividend in 3 days. The ex-dividend date is commonly two business...

HIAG Immobilien Holding AG ( VTX:HIAG ) is about to trade ex-dividend in the next 3 days. The ex-dividend date is...

Roche Holding (SWX:ROG) has drawn fresh investor attention after the FDA accepted its supplemental Biologics License Application for Gazyva/Gazyvaro in systemic lupus erythematosus and the company expanded its oncology research collaboration with C4 Therapeutics. See our latest analysis for Roche Holding. The recent FDA sBLA acceptance for Gazyva/Gazyvaro in systemic lupus erythematosus and the new degrader antibody collaboration with C4 Therapeutics come after a mixed stretch for the shares,...

Wondering whether Lonza Group at around CHF 508 per share offers value, or if the price still looks rich? This article walks through the numbers so you can judge that for yourself. The stock has had a mixed run, with a 4.8% decline over the last week, an 8.7% gain over the last 30 days, and a 1-year return of an 8.9% decline, which may signal shifting views on both risk and opportunity. Recent coverage has focused on Lonza Group's position in the life sciences sector and how investors are...

VAT Group (SWX:VACN) reaffirmed its 2026 outlook after issuing second quarter sales guidance of CHF 265 million to CHF 295 million, even as first quarter 2026 sales of CHF 221 million showed a year on year decline. See our latest analysis for VAT Group. VAT Group's share price has climbed 13.27% over the past 30 days and 35.78% year to date, while the 1 year total shareholder return of 111.39% points to strong momentum following the reaffirmed 2026 outlook and AI driven semiconductor demand...

Peach Property Group (SWX:PEAN) has just reported first half FY 2025 revenue of €69.975 million with a basic EPS loss of €0.26, setting a cautious tone around profitability at a share price of €5.90. The business has seen revenue move from €69.041 million in the first half of 2024 to €73.379 million in the second half of 2024 and then to €69.975 million in the latest period. Basic EPS losses widened from €1.05 in the first half of 2024 to €4.11 in the second half before moderating to €0.26,...

Avolta (SWX:AVOL) is back on investors’ radars after recent share price swings, with the stock posting a 4.5% decline over the past week but a small gain over the past month. See our latest analysis for Avolta. Zooming out, Avolta’s recent 7 day share price return of negative 6.4% and 1 day drop of 4.5% come after a 1 year total shareholder return of 31.9%. This suggests momentum has cooled but longer term holders are still ahead. If you are weighing Avolta’s swings against other...